打字猴:1.700629684e+09
1700629684 [13] Fass R, Fennerty MB, Ofman JJ, et al. The clinical and economic value of a short course of omeprazole in patients with moneardiac chest pain. Gastroenterology, 1998, 115(1):42-49.
1700629685
1700629686 [14] O’connor JF, Singer ME, Richter JE. The cost effectiveness of strategies to assess gastroesophageal reflux as an exacerbating factor in asthma. Am J Gastroenterol, 1999, 94(6):1472-1480.
1700629687
1700629688 [15] Olbe L, Lundell L. Medical treatment of reflux esophagitis. Hepatogastroenterology, 1992, 39(4):322-324.
1700629689
1700629690 [16] Lundell L. Acid suppression in the long term treatment of peptic stricture and Barrett’s oesophagus. Digestion, 1992, 51:49-58.
1700629691
1700629692 [17] Collen MJ, Lewis JH, Benjamin SB. Gastric acid hypersecretion in refractory gastroesophageal reflux disease. Gastroenterology, 1990, 98(3):654-661.
1700629693
1700629694 [18] Devault KR, Castell Do. Guidelines for the diagnosis and treatment of Practice Parameters Committee of the American College of Gastroenterology. Arch Intern Med, 1995, 155:2165-2173.
1700629695
1700629696 [19] Ikuo H, Joel ER. ACG practice guidelines: esophageal reflux testing. Am J Gastroenterol, 2007, 102:668.
1700629697
1700629698 [20] Cloud ML, Offen WW, Robinson M. Nizatidine versus placebo in gastroesophageal reflux disease: A 12 week, multicenter, randomized, double blind study. Am J Gastroenterol, 1991, 86(12):1735-1742.
1700629699
1700629700 [21] Klinkenberg Knol EC, Jansen JM, Festen HP, et al. Double blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis. Lancet, 1987, 1(8529):349-351.
1700629701
1700629702 [22] Vantrappen G, Rutgeerts L, Schurmans P, et al. Omeprazole（40mg）is superior to ranitidine in short term treatment of ulcerative reflux esophagitis. Dig Dis Sci, 1988, 33(50):523-529.
1700629703
1700629704 [23] Bate CM, Green JR, Axon AT, et al. Omeprazole is more effective than cimetidine in the prevention of recurrenee of GERD associated heartburn and the occurrence of underlying oesophagitis. Aliment Pharmacol Ther, 1998, 12(1):41-47.
1700629705
1700629706 [24] Chiba N, De Gara CJ, Wikinson JM, et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta analysis. Gastroenterology, 1997, 112(6):1798-1810.
1700629707
1700629708 [25] Castell DO, Richter JE, Robinson M, et al. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. The Lansoprazole Group. Am J Gastroenterol, 1996, 91(9):1749-1757.
1700629709
1700629710 [26] Dekkers CP, Beker JA, Thjodleifsson B, et al. Double blind comparison of raveprazole 20mg vs. omeprazole 20mg in the treatment of erosive or ulcerative gastro oesophageal reflux disease. The European Raveprazole Study Group. Aliment Pharmacol Ther, 1999, 13(1):49-57.
1700629711
1700629712 [27] Mee AS, Rowley JL. Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole. Aliment Pharmacol Ther, 1996, 10(5):757-763.
1700629713
1700629714 [28] Jancezewska I, Sagar M, Sjostedt S, et al. Comparison of the effect of lansoprazole and omeprazole on intragastric acidity and gastroesophageal reflux disease. Scand J Gastroenterol, 1998, 33(12):1239-1243.
1700629715
1700629716 [29] Thoring M, Hedenstrom H, Eriksson LS. Rapid effect of lansoprazole intragastric pH: a crossover comparison of omeprazole. Scand J Gastroenterol, 1999, 34(4):341.
1700629717
1700629718 [30] Richter JE, Long JF. Cisaprice for gastroesophageal reflux disease: A placebo controlled, double blind study. Am J Gastroenterol, 1995, 90(3):423-430.
1700629719
1700629720 [31] Miyamoto M, Haruma K, Takeuchi K, et al. Frequency scale for symptoms of gastroesophageal reflux disease predicts the need for addition of pmkinetics to proton pump inhibitor therapy. J Gastroenteml Hepatol, 2007, 19（online published).
1700629721
1700629722 [32] Hameeteman W. Clinical studies of Sucralfate in reflux esophagitis. The European experience. J Clin Gastroenterol, 1991, 1313:s16-s20.
1700629723
1700629724 [33] Howden CW, Castell Do, Cohen S, et al. The rationale for continuous maintenance treatment of reflux esophagitis. Arch Intern Med, 1995, 155(14):1465-1471.
1700629725
1700629726 [34] Kenneth R, Devault, MD. Overview of medical therapy for GERD. Gastroenterol Clin North Am. 1999, 28(4):831-845.
1700629727
1700629728 [35] 王良静，赵岚，姒健敏．不同联合疗法对反流性食管炎的疗效、生活质量和经济投入．中华内科杂志，2002，41(7):485-486.
1700629729
1700629730 [36] Vigneris, Termini R, Leandro G, et al. A comparison of five maintenace therapies for reflux esophagitis. N Engl J Med, 1995, 333(17):1106-1110.
1700629731
1700629732 [37] Harris RA, Kupprtmann M, Richter JE. Proton pump inhibitors histamine 2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost effectiveness analysis. Am J Gastroenterol, 1997, 92(12):2179-2187.
1700629733
[ 上一页 ]  [ :1.700629684e+09 ]  [ 下一页 ]